1. Home
  2. CAN vs ASMB Comparison

CAN vs ASMB Comparison

Compare CAN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAN

Canaan Inc.

HOLD

Current Price

$0.42

Market Cap

486.0M

Sector

Technology

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$27.45

Market Cap

440.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAN
ASMB
Founded
2013
2005
Country
Singapore
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
486.0M
440.0M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
CAN
ASMB
Price
$0.42
$27.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$3.21
$43.40
AVG Volume (30 Days)
9.1M
61.2K
Earning Date
05-19-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$63.64
$274.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$7.76
52 Week High
$2.22
$39.71

Technical Indicators

Market Signals
Indicator
CAN
ASMB
Relative Strength Index (RSI) 40.92 46.42
Support Level $0.43 $27.10
Resistance Level $0.55 $30.54
Average True Range (ATR) 0.03 1.41
MACD -0.00 -0.12
Stochastic Oscillator 25.79 33.71

Price Performance

Historical Comparison
CAN
ASMB

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: